TVTX position history
The shares of Travere Therapeutics (TVTX) that Palo Alto Investors LP reported in each quarter’s 13F.
Shares held by quarter
New Add Reduce Exit
- 2021 Q3: 166,069 shares, $4M, 0.24% of portfolio
- 2021 Q4: 166,069 shares, $5.2M, 0.33% of portfolio
- 2022 Q1: 166,069 shares, $4.3M, 0.33% of portfolio
- 2022 Q2: 166,069 shares, $4M, 0.35% of portfolio
- 2022 Q3: 166,069 shares, $4.1M, 0.32% of portfolio
- 2022 Q4: 166,069 shares, $3.5M, 0.30% of portfolio
- 2023 Q1: 166,069 shares, $3.7M, 0.31% of portfolio
- 2023 Q2: 166,069 shares, $2.6M, 0.21% of portfolio
- 2023 Q3: 166,069 shares, $1.5M, 0.14% of portfolio
- 2023 Q4: 221,438 shares, $2M, 0.18% of portfolio, Add +33.3%
- 2024 Q1: 110,719 shares, $854K, 0.10% of portfolio, Reduce −50.0%
- 2024 Q2: 110,719 shares, $910K, 0.11% of portfolio
- 2024 Q3: 110,719 shares, $1.5M, 0.20% of portfolio
- 2024 Q4: 110,719 shares, $1.9M, 0.30% of portfolio
- 2025 Q1: 110,719 shares, $2M, 0.38% of portfolio
- 2025 Q2: 110,719 shares, $1.6M, 0.35% of portfolio
- 2025 Q3: 110,719 shares, $2.6M, 0.49% of portfolio
- 2025 Q4: 110,719 shares, $4.2M, 0.59% of portfolio
- 2026 Q1: 230,453 shares, $6.8M, 1.0% of portfolio, Add +108.1%
- 2026 Q2: 167,525 shares, $9.5M, 1.3% of portfolio, Reduce −27.3%
- 2026 Q3: 158,946 shares, $9.4M, 1.4% of portfolio, Reduce −5.1%
| Holdings date | Value | % of holdings | Shares | Filing date | All 13F holders |
|---|